Please login to the form below

Not currently logged in
Email:
Password:

UniQure

This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer enters late-stage haemophilia B gene therapy trial

Pfizer has begun testing investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B, triggering a race against Dutch biotech UniQure. ... The news of the phase III programme comes hot on the heels of UniQure’s haemophilia B

Latest news

More from news
Approximately 8 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for

  • Pharma deals in April 2015 Pharma deals in April 2015

    BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.

  • Anticipating the future in healthcare Anticipating the future in healthcare

    The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics